Centro de Genética Médica Doutor Jacinto de Magalhães, INSA, I.P., Praça Pedro Nunes 88, Porto, Portugal.
Clin Genet. 2012 Apr;81(4):379-93. doi: 10.1111/j.1399-0004.2011.01625.x. Epub 2011 Mar 1.
The functional activity of lysosomal enzymes sialidase, β-galactosidase and N-acetylaminogalacto-6-sulfate-sulfatase in the cell depends on their association in a multienzyme complex with cathepsin A. Mutations in any of the components of this complex result in functional deficiency thereby causing severe lysosomal storage disorders. Here, we report the molecular defects underlying sialidosis (mutations in sialidase; gene NEU1), galactosialidosis (mutations in cathepsin A; gene PPGB) and GM1 gangliosidosis (mutations in β-galactosidase; gene GLB1) in Portuguese patients. We performed molecular studies of the PPGB, NEU1 and GLB1 genes in biochemically diagnosed Portuguese patients. Gene expression was determined and the effect of each mutation predicted at protein levels. In the NEU1 gene, we found three novel missense mutations (p.P200L, p.D234N and p.Q282H) and one nonsense mutation (p.R341X). In the PPGB gene, we identified two missense mutations, one novel (p.G86V) and one already described (p.V104M), as well as two new deletions (c.230delC and c.991-992delT) that give rise to non-functional proteins. We also present the first molecular evidence of a causal missense mutation localized to the cathepsin A active site. Finally, in the GLB1 gene, we found six different mutations, all of them previously described (p.R59H, p.R201H, p.H281Y, p.W527X, c.1572-1577InsG and c.845-846delC). Seven novel mutations are reported here, contributing to our knowledge of the mutational spectrum of these diseases and to a better understanding of the genetics of the lysosomal multienzymatic complex. The results of this study will allow carrier detection in affected families and prenatal molecular diagnosis, leading to the improvement of genetic counseling.
溶酶体酶唾液酸酶、β-半乳糖苷酶和 N-乙酰氨基半乳糖-6-硫酸酯-6-硫酸酯酶的功能活性取决于它们与组织蛋白酶 A 形成多酶复合物的结合。该复合物的任何成分发生突变都会导致功能缺陷,从而导致严重的溶酶体贮积症。在这里,我们报告了葡萄牙患者唾液酸酶缺乏症(唾液酸酶基因突变;基因 NEU1)、半乳糖唾液酸酶缺乏症(组织蛋白酶 A 基因突变;基因 PPGB)和 GM1 神经节苷脂病(β-半乳糖苷酶基因突变;基因 GLB1)的分子缺陷。我们对生化诊断为葡萄牙患者的 PPGB、NEU1 和 GLB1 基因进行了分子研究。确定了基因表达,并在蛋白质水平上预测了每种突变的影响。在 NEU1 基因中,我们发现了三个新的错义突变(p.P200L、p.D234N 和 p.Q282H)和一个无义突变(p.R341X)。在 PPGB 基因中,我们鉴定了两个错义突变,一个新的(p.G86V)和一个已经描述的(p.V104M),以及两个新的缺失(c.230delC 和 c.991-992delT),导致无功能蛋白。我们还首次提供了位于组织蛋白酶 A 活性部位的因果错义突变的分子证据。最后,在 GLB1 基因中,我们发现了六个不同的突变,都是以前描述过的(p.R59H、p.R201H、p.H281Y、p.W527X、c.1572-1577InsG 和 c.845-846delC)。这里报告了七个新的突变,有助于我们了解这些疾病的突变谱,并更好地理解溶酶体多酶复合物的遗传学。这项研究的结果将允许在受影响的家庭中进行携带者检测和产前分子诊断,从而改善遗传咨询。